坤泰胶囊联合亮丙瑞林治疗子宫内膜异位症的疗效观察

目的探讨坤泰胶囊联合醋酸亮丙瑞林缓释微球治疗子宫内膜异位症的安全性和有效性。方法选取郑州颐和医院2015年8月—2016年8月收治的子宫内膜异位症患者183例,随机分成对照组(91例)和治疗组(92例)。对照组患者皮下注射注射用醋酸亮丙瑞林缓释微球,于经期开始5 d内注射3.75 mg,每28天注射1次;治疗组在对照组的基础上口服坤泰胶囊,4粒/次,3次/d,两组均连续治疗3个月。分析评价两组患者治疗前后临床疗效、体内性激素水平、Kuppeman评分、VAS评分以及不良反应情况。结果治疗后,对照组和治疗组总有效率分别为82.42%、96.74%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者雌二醇、黄体生成激素以及卵泡生成素水平均明显降低(P0.05);且治疗组患者性激素水平明显优于对照组患者(P0.05)。治疗后,两组患者Kuppeman评分明显升高,VAS评分明显降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组患者Kuppeman评分和VAS评分改善情况要明显优于对照组患者,两组比较差异具有统计学意义(P0.05)。治疗期间对照组患者不良反应发生率为37.36%,显著高于治疗组的15.22%,两组比较差异具有统计学意义(P0.05)。结论坤泰胶囊联合醋酸亮丙瑞林缓释微球治疗子宫内膜异位症疗效好、安全性高,具有一定的临床推广应用价值。

Clinical observation of Kuntai Capsules combined with leuramide in treatment of endometriosis

Objective To explore the safety and efficacy of Kuntai Capsules combined with leuramide in treatment of endometriosis. Methods Patients (183 cases) with endometriosis in Zhengzhou Yihe Hospital Affiliated to Henan University from August 2015 to August 2016 were randomly divided into control (91 cases) and treatment (92 cases) groups. Patients in the control group were sc injected with Leuprorelin Acetate Microspheres Sustained Release for injection, 3.75 mg injected in 5 d after menstruation, once every 28 d. Patients in the treatment group were po administered with Kuntai Capsules on the basis of control group, 4 grains/time, three times daily. Patients in two groups were treated for three months. After treatment, the clinical efficacy, sex hormone level, Kuppeman and VAS scores, and adverse reaction in two groups before and after treatment were analyzed and evaluated. Results After treatment, the clinical efficacies in the control and treatment groups were 82.42% and 96.74% respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of estradiol, luteinizing and follicle stimulating hormone in two groups were significantly decreased (P < 0.05). And the sex hormone level in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, Kuppeman scores in two groups were significantly increased, but VAS score was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the improvement effect of Kuppeman and VAS scores in the treatment group was significantly better than that in the control group, with significant difference between two groups (P < 0.05). During the treatment, the adverse reaction in the control group was 37.36%, which was significantly higher than 15.22% in the treatment group, and there were differences between two groups (P < 0.05). Conclusion Kuntai Capsules combined with leuramide have good curative effect and safety in treatment of endometriosis, which has a certain clinical application value.